New Study Identifies Potential Therapeutic Target for Gastric Cancer
Retrieved on:
Monday, June 6, 2022
Cell division, Drug resistance, Immunohistochemistry, Experimental Biology and Medicine, Experimental Biology and Medicine (Society for Experimental Biology and Medicine journal), Neoplasm, Nantong University, Publishing, Drug tolerance, Society, Stomach cancer, Hereditary diffuse gastric cancer, Therapy, Stomach, BVES, Cell adhesion, GLOBE, Patient, Experimental biology, Mortality, Movement, PDX, Institute, Cancer, Medical device, Pharmaceutical industry, MSI1, Medicine
Drug resistance accounts for most of the mortality of gastric cancer.
Key Points:
- Drug resistance accounts for most of the mortality of gastric cancer.
- Musashi-1 (MSI1) is an RNA-binding protein that is considered a gastric and intestinal stem cell marker and may act as a biomarker and therapeutic target for gastric cancer.
- Therefore, the authors posited that a clear understanding of the role of MSI1 in gastric cancers may lead to more effective therapeutics for treating gastric cancer.
- Our study provides a strategy for the development of personalized treatment for gastric cancer patients and offers potential value in predicting chemosensitivity in tumors."